Affordable Access

deepdyve-link
Publisher Website

Medulloblastoma genomics in the modern molecular era.

Authors
  • Kumar, Rahul1, 2
  • Liu, Anthony P Y1, 3
  • Northcott, Paul A1
  • 1 Department of Developmental Neurobiology, Division of Brain Tumor Research, St. Jude Children's Research Hospital, Memphis, TN.
  • 2 St. Jude Graduate School of Biomedical Sciences, Memphis, TN.
  • 3 Department of Oncology, Division of Neurooncology, St. Jude Children's Research Hospital, Memphis, TN.
Type
Published Article
Journal
Brain Pathology
Publisher
Wiley (Blackwell Publishing)
Publication Date
Dec 04, 2019
Identifiers
DOI: 10.1111/bpa.12804
PMID: 31799776
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Medulloblastoma (MB) represents a spectrum of biologically and clinically distinct entities. Initially described histopathologically as a small, round blue cell tumor arising in the cerebellum, MB has emerged as a paradigm for molecular classification in cancer. Recent advances in genomic, transcriptomic and epigenomic profiling of MB have further refined molecular classification and complemented conventional histopathological diagnosis. Herein, we review the main clinical and molecular features of the four consensus subgroups of MB (WNT, SHH, Group 3 and Group 4). We also highlight hereditary predisposition syndromes associated with increased risk of MB. Finally, we explore advances in the classification of the consensus molecular groups while also presenting cutting-edge frontiers in identifying intratumoral heterogeneity and cellular origins of MB. © 2019 International Society of Neuropathology.

Report this publication

Statistics

Seen <100 times